Navigation Links
Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
Date:8/14/2008

- Company to Host Conference Call at 4:30 p.m. ET Today -

SUNNYVALE, Calif., Aug. 14 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its fourth quarter and fiscal year ended June 30, 2008. The net loss for the fourth quarter of fiscal 2008 was $4.6 million, or $0.18 per share, compared to a net loss of $7.0 million, or $0.27 per share, for the fourth quarter of fiscal 2007.

Total operating expenses were $4.8 million for the fourth quarter of fiscal 2008 compared to $7.6 million for the fourth quarter of fiscal 2007. Share-based compensation expense was $0.5 million in the fourth quarter of fiscal 2008 compared to $0.8 million in the fourth quarter of fiscal 2007. The decrease in total operating expenses in the fourth quarter of fiscal 2008 was primarily related to reduced personnel expenses due to lower headcount, lower outside clinical trial costs and reduced preclinical expenses associated with the company's Factor VIIa inhibitor program due to the completion of preclinical activities.

Pharmacyclics also reported financial results for the fiscal year ended June 30, 2008. The net loss for the fiscal year ended June 30, 2008 was $24.3 million, or $0.93 per share. This compares to a net loss of $26.2 million, or $1.08 per share, for fiscal year 2007.

As of June 30, 2008, the company had cash, cash equivalents and marketable securities totaling $16.8 million. This compares to $38.8 million in cash, cash equivalents and marketable securities as of June 30, 2007.

Fiscal 2009 Guidance

Pharmacyclics projects total operating expenses, excluding share-based compensation, of between $14 and $15 million for fiscal year 2009, including general and admini
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
2. Pharmacyclics Announces It Received Nasdaq Notification
3. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. QMed, Inc. Reports July Medicare SNP Enrollments
6. Phlo Affiliate Reports Expanded Coverage to Oregon Border
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
9. Carrington Reports Second Quarter 2007 Results
10. Avitar Reports Third Quarter Financial Results for Fiscal 2007
11. Response Genetics Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... Texas , March 29, 2015 /PRNewswire/ ... presentation of important study data showing the ... in 1,599 gynecologic cancer samples. Using Caris ... profiling service, researchers identified expression of programmed ... cancers independent of histology while its ligand ...
(Date:3/27/2015)... March 27, 2015 Earlier this year, ... promotion of hair regrowth in adult men and women ... or Norwood Hamilton classifications of IIa-V and Fitzpatrick Classification ... plagued by products that over-promise and under-deliver, FDA Clearance ... faith and confidence among more than 80 million men ...
(Date:3/27/2015)... 27. März 2015  Peter Walter wurde ... Science für seine bahnbrechende Arbeit ausgewählt, die ... transportiert werden, sowie für die Entschlüsselung der ... auf Stress nutzen, der mit der Ansammlung ... Professor für Biochemie an der University of ...
(Date:3/27/2015)... 2015   SurePure, Inc . (OTCQB: SURP), ... that the Company has completed the verification process ... SurePure ("SURP") securities on OTCQB, an electronic quote ... development stage companies. On March 26, ... requirements designed to improve marketplace integrity and enhance ...
Breaking Biology Technology:Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 2Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 4Dr. Robert Leonard Applauds FDA Clearance of Capillus272Pro™ Hair Loss Laser Cap 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4SurePure Completes Verification and Approved for Trading on the OTCQB Marketplace 2
... , , LA JOLLA, Calif., ... molecular diagnostics for the early detection of disease plus additional ... of a feasibility study using DermTech,s advanced EGIR(TM) technology to ... The two companies will now move forward with a proof-of-concept ...
... , CALGARY, July 15 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ... that a poster presentation by Dr. Jacqueline Parker et ... in Combination with Temozolomide and Low Dose Irradiation in ... Therapy Alone" was made yesterday at the 28th American ...
... PRINCETON, N.J., July 15 BioWa, Inc. announced today that ... Darmstadt, Germany, providing the global healthcare and chemicals company with ... and commercialization of their antibody therapies with enhanced antibody-dependent cellular ... "We are extremely pleased about our partnership with Merck KGaA, ...
Cached Biology Technology:DermTech and Stiefel Laboratories, Inc. to Further Evaluate EGIR(TM) Technology 2DermTech and Stiefel Laboratories, Inc. to Further Evaluate EGIR(TM) Technology 3Oncolytics Biotech(R) Inc. Research Collaborators Present Glioma Reovirus Research at ASV Annual Meeting 2BioWa Announces License of POTELLIGENT(R) Technology to Merck KGaA 2
(Date:3/23/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet, ... March 30 th . The new ... York markets. Gino Pereira ... new ad campaign following the recent initial shipment of Wocket ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Hand Geometry - Global Strategic Business Report" report to ... for Hand Geometry in US$ Thousands. The report provides separate ... Japan , Europe , ... , and Rest of World. Annual estimates and ...
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced ... Business Report" report to their offering. This ... Thousands. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... America . Annual estimates and forecasts are ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... researchers from 80 countries, the world,s scientists as well as ... Life, which provides the first in-depth look at the more ... of Marine Life initiative, started in 2000, is the result of ... of more than 540 expeditions and 9,000 days at sea, plus ...
... The new center is a continuum for the Center ... VTT in Finland. The center in So Paulo aims to ... American market. Important focus areas will be biomass, bioethanol, pulp ... R&D center in So Paulo is the fourth part in ...
... , Washington, D.C. (October 5, 2010) -- A prototype ... to non-invasively test drugs for their ability to kill ... The new device is built upon microfluidics -- a ... of fluids at the sub-millimeter scale -- and is ...
Cached Biology News:San Diego Supercomputer Center participates in first 'Census of Marine Life' 2Kemira and VTT to open a joint R&D center in Brazil 2Anti-tumor drugs tested by microfluidic device 2
... large numbers of samples may be carried out ... which requires minimum operator attention. System control ... and interface CE 4900. The elegant, powerful ... Windows XP and Windows 98 and 2000., The ...
... Highly nutritious peptone, used ... production of bacterial toxins, ... of bacteria with high ... Haemophilus, Neisseria, Pasteurella, Salmonella ...
... Human Raji cells were cultured in RPMI 1640 ... the log phase of growth. In order ... cells were fixed in acetone-methanol. The cells ... coated slide, with each wells surface specifically treated ...
... Human 293 cells were cultured in Minimum ... harvested at the log phase of growth. ... native forms, cells were fixed in acetone-methanol. ... mm) adhesive coated slide, with each wells surface ...
Biology Products: